See Supplemental Patient Information
- Anaphylaxis has been observed in patients receiving taliglucerase alfa; immediately discontinue therapy and institute appropriate medical treatment if anaphylaxis occurs. Caution should be exercised upon rechallenging therapy in patients who have experienced anaphylaxis during prior infusion; keep appropriate medical support readily available
- If infusion reactions such as headache, chest pain or discomfort, asthenia, fatigue, urticaria, erythema, hypertension, back pain, arthralgia, and flushing occur, manage the patient depending on type and severity of the reaction by slowing the infusion rate or treatment with medications such as antihistamines and/or antipyretics
- Make dose adjustments based on individual patient's therapeutic goals
- Premedicate patients with antihistamines and/or corticosteroids to prevent subsequent reactions in cases where symptomatic treatment is required
- Therapy may lead to development of IgG anti-drug antibodies (ADA), which may be associated with a higher risk of infusion reactions
- Periodically monitor IgG ADA formation in patients who develop infusion or immune reactions with taliglucerase therapy
Cautions: Use cautiously in
Supplemental Patient Information
- Advise patients to promptly report to their physician if any adverse reactions occur while on taliglucerase therapy
Pregnancy Category:B
Breastfeeding: Safety unknown. Manufacturer advises caution.
